2.06

1.48% 0.03

After Hours: 2.06

Abcellera Biologics Inc (ABCL)

Overview News Price History Option Chain Financials Why ABCL Down? Discussions Forecast

Abcellera Biologics Inc stock is traded at $2.06, with a volume of 4.39M. It is up +1.48% in the last 24 hours and down -14.17% over the past month. AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.

Previous Close:

$2.03

Open:

$2.12

24h Volume:

4.39M

Relative Volume:

1.06

Market Cap:

$653.68M

Revenue:

$38.03M

Net Income/Loss:

$-146.40M

P/E Ratio:

-3.9615

EPS:

-0.52

Net Cash Flow:

$-121.38M

1W Performance:

-5.94%

1M Performance:

-14.17%

6M Performance:

-30.41%

1Y Performance:

-46.21%

1-Day Range:

$2.04

$2.1492

1-Week Range:

$1.98

$2.1892

52-Week Range:

$1.8906

$4.3398

Abcellera Biologics Inc Stock (ABCL) Company Profile

Name

Abcellera Biologics Inc

Sector

Healthcare (1154)

Industry

Biotechnology (676)

Phone

(604) 559-9005

Address

150 W 4TH AVENUE, VANCOUVER

Employee

596

Twitter

Next Earnings Date

2024-11-18

Latest SEC Filings

ABCL's Discussions on Twitter

Compare ABCL with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ABCL Abcellera Biologics Inc	2.06	653.68M	38.03M	-146.40M	-121.38M	-0.52
VRTX Vertex Pharmaceuticals Inc	439.37	128.45B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	575.63	65.17B	14.09B	4.50B	2.96B	39.28
ARGX Argen X Se Adr	560.90	40.09B	2.58B	1.06B	-1.28B	16.33
ALNY Alnylam Pharmaceuticals Inc	270.19	35.67B	2.35B	-269.70M	-75.39M	-2.09
ONC Beigene Ltd Adr	233.25	27.44B	3.81B	-644.79M	-669.77M	-6.24

Abcellera Biologics Inc Stock (ABCL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-20-24	Downgrade	The Benchmark Company	Buy → Hold
Feb-22-24	Upgrade	The Benchmark Company	Hold → Buy
Dec-05-23	Initiated	KeyBanc Capital Markets	Overweight
Nov-06-23	Downgrade	The Benchmark Company	Buy → Hold
Oct-13-23	Resumed	Piper Sandler	Overweight
Feb-28-23	Initiated	Cowen	Outperform
Dec-15-22	Initiated	Goldman	Buy
Nov-16-22	Initiated	Truist	Buy
Dec-21-21	Initiated	The Benchmark Company	Buy
Nov-19-21	Initiated	Piper Sandler	Overweight
Jan-05-21	Initiated	BMO Capital Markets	Outperform
Jan-05-21	Initiated	Berenberg	Buy
Jan-05-21	Initiated	Credit Suisse	Outperform
Jan-05-21	Initiated	SVB Leerink	Outperform
Jan-05-21	Initiated	Stifel	Buy

View All

Abcellera Biologics Inc Stock (ABCL) Latest News

May 12, 2025

Abcellera's Microfluidic Cell Culture Patent Affirmed Valid By U.S. Court Of Appeals For Federal Circuit - marketscreener.com

May 12, 2025

AbCellera’s Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit - Business Wire

May 12, 2025

May 11, 2025

AbCellera plans to advance ABCL635 and ABCL575 into Phase 1 trials in Q3 2025 - MSN

May 11, 2025

May 10, 2025

AbCellera Biologics Inc. (NASDAQ:ABCL) Q1 2025 Earnings Call Transcript - Insider Monkey

May 10, 2025

AbCellera Presents Positive Preclinical Data on ABCL575 at the 2 - GuruFocus

May 10, 2025

Stifel Adjusts Price Target for AbCellera (ABCL), Maintains Buy Rating | ABCL Stock News - GuruFocus

May 10, 2025

AbCellera Biologics Navigates Progress and Challenges in Earnings Call - TipRanks

May 10, 2025

May 09, 2025